Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by Pragmatiston Feb 19, 2021 5:16pm
295 Views
Post# 32613304

RE:I asked Dan when we will go to Nasdaq...Great answer

RE:I asked Dan when we will go to Nasdaq...Great answer
Marky1 wrote:
Marky1 Life is not dissimilar to the machinations in any (pre-pandemic) bar…or for that matter, any typical M&A deal... To pick someone up, you don’t look eager. You be mighty cool. And timing. You don’t rush. Most US companies who go on to Nasdaq do not trade well post-list. You and your friends seem to think an uplist to Nasdaq is a panacea…it’s fraught with difficulty. One has to be very strategic about it. The stronger we are, and the less we need it, and the more ground fertilization and watering, the better we’ll do (post-listing!! Which is everything). We’ll get better I-banks, with better buy-in on-deal and post-deal, we’ll get better terms and we’ll do better post-list. We don’t care if our stock is up or down between, say, March 10-15. We’re going for the real thing. (And it’s no longer ‘long term’ – the long term is upon us. (But relatively speaking). ( I know you look at the stock every day – but I don’t! I want us to be a billion market cap, soon. But tomorrow? Couldn’t care less. Nasdaq is very valuable for us…but on our terms. Cheers, D
0

Thankyou for sharing that Marky.  
 
He confirmed what I said in a recent post:
" Getting to Nasdaq is the easy part. Sustaining SP and institutional investor interest after is more challenging."
 
Because of his measured approach, we can be confident that SP post-uplist will be sustainable. This is good.
 
For those who are interested in scratching deeper, the following refs give some actual data based on historical perfromance.
 
 
https://seekingalpha.com/article/3957442-uplisting-power
 
https://seekingalpha.com/article/4312617-look-stocks-are-planning-to-uplist
 
<< Previous
Bullboard Posts
Next >>